PRISM BioLab (206A) · TargetAdvancedLatest Earnings (2026-05-14): "Restated"
Identify clinical candidate compounds using FEP within 1–2 years
First written in FY2024. 1 of 3 entries say "Advanced", first in FY2025. Latest entry: 2026-05-14.
3entries
3years
1from disclosures
How it moved
Same theme, other companies
Clinical Candidate Generation for 4E-BP1 Mimetic Compounds Using FEPA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-05-14RestatedEarnings
「Drug discovery research is being conducted at the “lead optimization” stage for a 4EBP1-mimetic compound program intended to inhibit the eIF4E/eIF4G PPI involved in “CAP-dependent translation,” on which signaling pathways activated in cancer cells strongly depend.」
FEP continued to be studied at the lead optimization stage. - FY2025AdvancedAnnual report
「Research on the 4EBP1-mimetic compound program, an inhibitor of eIF4E/eIF4G that we have been advancing, is being conducted at the lead optimization stage.」
Research on FEP continues at the lead optimization stage. The company has set internal targets of creating optimized lead compounds and clinical candidate compounds at an early stage, and signing an out-licensing agreement after obtaining key compounds. - FY2024First statedAnnual report
「We aim to advance optimization, including through the use of AI, and identify a clinical candidate compound within 1–2 years.」
For 4E-BP1-mimetic compounds that modulate eIF4E/eIF4G, optimization synthesis has resumed following reconstruction of the assay system.